What is Oxytocic Pharmaceuticals Market?
Oxytocic drugs are used at the end of pregnancy, during labor pain, and post-delivery which induce to take a selective action on the contraction of smooth musculature of the uterus. Oxytocic drugs are used in various fields of obstetrics such as induction of labor, contraction stress test, treatment of labor arrest, management of labor, and the treatment of uterine atony and postpartum hemorrhage. The drug is also used to abort the fetus in case of miscarriage. This has led to significant growth of the global oxytocic pharmaceuticals market in the forecast period.
The market study is being classified and major geographies with country level break-up.
Fresenius Kabi AG (Germany), Baxter Healthcare Corporation (United States), Pfizer Inc. (United States), Ferring Pharmaceuticals (Switzerland), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. ( Israel), APP Pharmaceuticals, LLC (United States), LBS Labs (Belgium) and JHP Pharmaceuticals, LLC (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oxytocic Pharmaceuticals market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Oxytocic Pharmaceuticals market by Type, Application and Region.
On the basis of geography, the market of Oxytocic Pharmaceuticals has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Childbirth using Labor Induction
- Increasing Cases of Pregnancy-related Complications Emerging in Developing Nations
- Growing Expansion of the Health Care and Pharmaceutical Industries in Developing Countries
- Availability of Alternative Drugs
- Rising Focus of Achieving Mortality Ratio of Less than 70 per 100,000 Live Births in Under-Resourced Regions
- Growing Research and Development in Use of Oxytocin at Lower Doses
- Quality Issues Associated with Oxytocin Preparations
Market Leaders and some development strategies
On 3rd July 2019, Dr. Reddy’s Laboratories has launched Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer).
On 31st May 2018, Granules Pharmaceuticals, Inc., the wholly-owned subsidiary of Granules India Ltd. partnered with West-Ward Pharmaceuticals Corp., a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, to launch the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine.
Key Target AudienceOxytocic Pharmaceuticals Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase